Healthcare utilisation and costs associated with adding montelukast to current therapy in patients with mild to moderate asthma and co-morbid allergic rhinitis: PRAACTICAL study

PharmacoEconomics

Volumn 25, Issue 8, 2007, Pages 665-676

  Dal Negro, Roberto ^a   Piskorz, Peter ^b   Vives, Roberto ^c   Guilera, Magda ^d   Kocevar, Vasilisa Sazonov ^e   Badia, Xavier ^d,f  

^a Bussolengo Hospital   (Italy)

^b Outpatient Clinic   (Poland)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d Health Outcomes Research Europe   (Spain)

^e MERCK RESEARCH LABORATORIES   (United States)

^f IQVIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIALLERGIC AGENT; ANTIINFECTIVE AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; MONTELUKAST;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DRUG COST; EMERGENCY CARE; FEMALE; HAY FEVER; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MILD PERSISTENT ASTHMA; MODERATE PERSISTENT ASTHMA; MULTICENTER STUDY; OUTPATIENT CARE; POLAND; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SPAIN;

ACETATES; ADOLESCENT; ADULT; ASTHMA; COHORT STUDIES; DELIVERY OF HEALTH CARE; FEMALE; HEALTH CARE COSTS; HUMANS; LEUKOTRIENE ANTAGONISTS; MALE; MIDDLE AGED; QUINOLINES; RETROSPECTIVE STUDIES; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL;

EID: 34547144305     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200725080-00004     Document Type: Article

References (40)

1. Burr ML, Butland BK, King S, et al. Changes in asthma prevalence: two surveys 15 years apart. Arch Dis Child 1989; 64 (10): 1452-6
2. Ciprandi G, Vizzaccaro A, Cirillo I, et al. Increase of asthma and allergic rhinitis prevalence in young Italian men. Int Arch Allergy Immunol 1996; 111 (3): 278-83
3. Upton MN, McConnachie A, McSharry C, et al. Intergenerational 20 year trends in the prevalence of asthma and hay fever in adults: the Midspan family study surveys of parents and offspring. BMJ 2000; 321 (7253): 88-92
4. Variations in the prevalence of respiratory symptoms, self-reported asthma attacks, and use of asthma medication in the European Community Respiratory Health Survey (ECRHS). Eur Respir J 1996; 9 (4): 687-95
5. Heinrich J, Richter K, Frye C, et al. European Community Respiratory Health Survey in Adults (ECRHS). Pneumologie 2002; 56 (5): 297-303
6. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108 (5 Suppl.): S147-334
7. Vinuya RZ. Upper airway disorders and asthma: a syndrome of airway inflammation. Ann Allergy Asthma Immunol 2002; 88 (4 Suppl. 1): 8-15
8. Braman SS, Barrows AA, DeCotiis BA, et al. Airway hyperresponsiveness in allergic rhinitis: a risk factor for asthma. Chest 1987; 91 (5): 671-4
9. Weiss KB, Sullivan SD. The health economics of asthma and rhinitis: I. Assessing the economic impact. J Allergy Clin Immunol 2001; 107 (1): 3-8
10. Yawn BP, Yunginger JW, Wollan PC, et al. Allergic rhinitis in Rochester, Minnesota residents with asthma: frequency and impact on health care charges. J Allergy Clin Immunol 1999; 103 (1 Pt 1): 54-9
11. Bousquet J, Gaugris S, Kocevar VS, et al. Increased risk of asthma attacks and emergency visits among asthma patients with allergic rhinitis: a subgroup analysis of the improving asthma control trial. Clin Exp Allergy 2005; 35 (6): 723-7
12. Price DB, Zhang Q, Sazonov Kocevar V, et al. Effect of a concomitant diagnosis of allergic rhinitis on asthma-related health care use by adults. Clin Exp Allergy 2005; 35: 282-7
13. Jain P, Golish JA. Clinical management of asthma in the 1990s: current therapy and new directions. Drugs 1996; 52 Suppl. 6: 1-11
14. Laviolette M, Malmstrom K, Lu S, et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/ Beclomethasone Additivity Group. Am J Respir Crit Care Med 1999; 160 (6): 1862-8
15. Price DB, Hernandez D, Magyar P, et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 2003; 58 (3): 211-6
16. Vaquerizo MJ, Casan P, Castillo J, et al. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax 2003; 58 (3): 204-10
17. Philip G, Nayak AS, Berger WE, et al. The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis. Curr Med Res Opin 2004; 20 (10): 1549-58
18. Chervinsky P, Philip G, Malice MP, et al. Montelukast for treating fall allergic rhinitis: effect of pollen exposure in 3 studies. Ann Allergy Asthma Immunol 2004; 92 (3): 367-73
19. EUROSTAT. Statistical Office of the European Communities [online]. Available from URL: http://epp.euro stat.cec.eu.int [Accessed 2004 Oct 11]
20. The new national pharmaceutical formulary 2003 [online]. Available from URL: http://www.ministerosalute.it [Accessed 2004 Oct 11]
21. Pharmindex kompendium lekóv [online]. Available from URL: http://www.ksiegarnia.bytom.pl/ks109326.php [Accessed 2004 Oct 11]
22. National Health Fund (NFZ) [online]. Available from URL: http://www.nfz.gov.pl [Accessed 2004 Oct 11]
23. Official Colleges of Pharmacists [online]. Available from URL: http://www.portalfarma.com [Accessed 2004 Oct 13]
24. Base de datos de costes sanitarios. Barcelona: Centro de estudios en Economía de la Salud y Política Social (SOIKOS), 2005
25. GINA guidelines: global initiative for asthma. A pocket guide for physicians and nurses [online]. Available from URL: http:// www.ginasthma.com/ [Accessed 2004 Oct 14]
26. ARIA workshop and WHO. ARIA guideline: management of allergic rhinitis and its impact on asthma. A pocket guide for physicians and nurses [online]. Available from URL: http:// www.guideline.gov [Accessed 2004 Oct 14]
27. Desgagne A, Castilloux AM, Angers JF, et al. The use of the bootstrap statistical method for the pharmacoeconomic cost analysis of skewed data. Pharmacoeconomics 1998; 13 (5): 487-97
28. Price DB, Ben Joseph RH, Zhang Q. Changes in asthma drug therapy costs for patients receiving chronic montelukast therapy in the UK. Respir Med 2001; 95 (1): 83-9
29. O'Connor RD, O'Donnell JC, Pinto LA, et al. Two-year retrospective economic evaluation of three dual-controller therapies used in the treatment of asthma. Chest 2002; 121 (4): 1028-35
30. Barnes N, Thomas M, Price D, et al. The national montelukast survey. J Allergy Clin Immunol 2005; 115 (1): 47-54
31. Simons FE, Villa JR, Lee BW, et al. Montelukast added to budesonide in children with persistent asthma: a randomized, double-blind, crossover study. J Pediatr 2001; 138 (5): 694-8
32. Lofdahl CG, Reiss TF, Leff JA, et al. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ 1999; 319 (7202): 87-90
33. Thomson NC, Shepherd M. Leukotriene receptor antagonists as add-on therapy for adults with asthma. Thorax 2003; 58 (3): 190-2
34. Bateman ED. Using clinical measures of disease control to reduce the burden of asthma. Pharmacoeconomics 2001; 19 Suppl. 2: 7-12
35. Mellis CM, Peat JK, Bauman AE, et al. The cost of asthma in New South Wales. Med J Aust 1991; 155 (8): 522-8
36. Thompson S. On the social cost of asthma. Eur J Respir Dis Suppl 1984; 136: 185-91
37. Serra-Batlles J, Plaza V, Morejon E, et al. Costs of asthma according to the degree of severity. Eur Respir J 1998; 12 (6): 1322-6
38. Berggren F. Assessing the use of retrospective databases in conducting economic evaluations of drugs: the case of asthma. Pharmacoeconomics 2004; 22 (12): 771-91
39. Storms W, Michele TM, Knorr B, et al. Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged 6 years. Clin Exp Allergy 2001; 31 (1): 77-87
40. Barnett AG, van der Pols JC, Dobson AJ. Regression to the mean: what it is and how to deal with it. Int J Epidemiol 2005; 34 (1): 215-20